Curasight A/S rights issue heavily oversubscribed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.
Copenhagen, Denmark, 3 October 2024 – The subscription period in Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) preferential rights issue of units consisting of warrants of series TO2 (”TO2”) and series TO3 (“TO3”) (the “Rights Issue”) ended on 30 September 2024. The Rights Issue was heavily oversubscribed by 17,299%. The majority of the rights issue (90% corresponding to 1,098,708 units) was subscribed to with unit rights and a further 209,410,287 units were subscribed to without unit rights. A formal decision on allocation is expected to take place today.
Outcome of the Rights Issue
The subscription period in the Rights Issue ended on 30 September 2024. The Rights Issue consisted of a maximum of 1,216,907 units, of which 1,098,708 units, corresponding to approximately 90 percent of the Rights Issue, have been subscribed for with the support of unit rights. In addition, a total of 209,410,287 units have been subscribed for without the support of unit rights, corresponding to approximately 17,208 percent of the Rights Issue. Together, the subscriptions correspond to 17,299 percent of the Rights Issue. The Rights Issue is thus heavily oversubscribed. Through the Rights Issue, the Company will receive DKK 12,169.07.
Allocation and payment
Notification of allocation will be communicated separately through each subscriber’s bank. Payment of subscribed and allocated units shall be made by cash payment in accordance with the instructions from the subscriber’s bank.
Shares and share capital
It is to be noted that the Rights Issue itself will not increase the number of shares or the share capital. Existing shareholders who have chosen not to participate in the Rights Issue will thus not experience a dilution effect after the Rights Issue.
Trading in paid subscribed units (“BTU”)
Trading in BTUs is ongoing until the conversion of BTUs into warrants of series TO2 and TO3, which will take place after the Rights Issue has been registered with the Danish Business Authority (Erhvervsstyrelsen).
Warrants of series TO2 and series TO3
Warrants of series TO2 will have an exercise period that runs from and including 21 November 2024 until and including 5 December 2024. The exercise price for warrants of series TO2 will be set on the day before the exercise period and will be based on the Volume Weighted Average Price in the Company's share 20 days back, with a discount of 30 percent and be within the range DKK 11.50-15.55. Through the exercise of warrants of series TO2, Curasight can receive a maximum of approximately DKK 57.3 million. The warrants of series TO2 will be subject to trading at Spotlight Stock Market.
If all the warrants of series TO2 are exercised, the share capital will increase by DKK 184,190.70 to DKK 1,218,312.05 and the number of shares will increase by 3,683,814 to 24,366,241, resulting in a dilution of approximately 15.1 percent.
Warrants of series TO3 will have an exercise period that runs from and including the 4 June 2025 until and including 18 June 2025. The exercise price for warrants of series TO3 will be set on the day before the exercise period and will be based on the Volume Weighted Average Price in the Company's share 20 days back, with a discount of 30 percent and be within the range DKK 15.55-19.40. Through the exercise of warrants of series TO3, Curasight can receive a maximum of approximately DKK 35.7 million. The warrants of series TO3 will be subject to trading at Spotlight Stock Market.
If all the warrants of series TO3 are exercised, the share capital will increase by an additional DKK 92,095.35 to DKK 1,310,407.40 and the number of shares will increase by an additional 1,841,907 to 26,208,148, resulting in a dilution of approximately 7.0 percent.
Advisors
Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor. Nordic Issuing AB is the settlement agent.
Important information
Publication or distribution of this press release may in some jurisdictions be subject to restrictions by law and persons in the jurisdictions where this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable regulations of the respective jurisdiction. This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities of the Company in any jurisdiction, either from the Company or from anyone else.
This press release neither identifies nor purports to identify risks (direct or indirect) that may be attributable to an investment in new securities. An investment decision due to the rights issue must be made on the basis of all publicly available information regarding the Company and the Company's shares. The information in this press release is published as background information only and does not claim to be complete. Accordingly, an investor should not rely solely on the information in this press release or its accuracy or completeness.
This press release does not constitute a recommendation for any investors' decisions regarding the Rights Issue. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this announcement and any publicly available information. The price and value of the securities may decrease as well as increase. Achieved results do not constitute a guide for future results.
This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without application of an exemption from registration, under the then-current U.S. Securities Act of 1933 ("Securities Act") and may not be offered or sold in the United States without being registered, subject to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, Belarus, Russia, the United States or any other jurisdiction where such publication , publication or distribution of this information would be contrary to current regulations or where such an action is subject to legal restrictions or would require additional registration or other measures than what follows from Danish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.dk
www.curasight.com
For more information regarding the Rights Issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.